title: Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study.
abstract: OBJECTIVE
  To evaluate the clinical efficacy of concurrent chemoradiotherapy (CCRT) using daily low-dose cisplatin for cervical cancer.
  
  
  METHODS
  Fifty-one patients with locally advanced cervical cancer (FIGO stage IB2, bulky IIA, IIB-IVA) who were treated with CCRT as primary therapy at Kurume University Hospital between 2000 and 2007 were retrospectively reviewed. CCRT consisted of 5 mg/m(2)/day of cisplatin 5 days per week, and external beam radiotherapy (EBRT) administrated to whole pelvis to 45-50.6 Gy. High-dose-rate intracavitary brachytherapy was delivered in a single dose of 4-5 Gy at point A, once a week after 20-30 Gy of EBRT.
  
  
  RESULTS
  The median follow-up duration was 42 months (range, 5 to 116 months). The overall response rate was 94.1%. Five year overall survival rate was 71.5% and 46.2% in stage I or II, and stage III or IVA, respectively. During follow-up period, 30 recurrences (58.8%) were found, the local failure rate was 39%, and distant failure rate was 35.2%, and both (local and distant) were 15.7%. Hematological toxicities were the most frequent acute toxicities. Grade 3 and 4 neutropenia was observed in 37.3%. Late intestinal toxicities appeared in 7 cases (13.7%), which occurred between 6 and 114 months after treatment. Four cases required bowel surgery.
  
  
  CONCLUSIONS
  CCRT using daily low-dose cisplatin was tolerable and showed favorable initial response as the primary therapy for locally advanced uterine cervical cancer. But there was no remarkable long-term benefit for patients' survival or local disease control in this study. The incidence of late intestinal toxicity still requires further investigation.
authors: Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan.
authors: Kimio
authors: K
authors: Ushijima
authors: Keizo
authors: K
authors: Fujiyoshi
authors: Kouichiro
authors: K
authors: Kawano
authors: Naotake
authors: N
authors: Tsuda
authors: Shin
authors: S
authors: Nishio
authors: Hidehiro
authors: H
authors: Eto
authors: Toshiharu
authors: T
authors: Kamura
keywords: Cervical cancer; Cisplatin; Concurrent chemoradiotherapy; Daily low-dose
references: Lancet. 2001 Sep 8;358(9284):781-6
references: 11564482
references: J Clin Oncol. 2008 Dec 10;26(35):5802-12
references: 19001332
references: Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
references: 7713792
references: Chin J Cancer. 2010 Nov;29(11):959-63
references: 20979696
references: Eur J Cancer. 2002 Jan;38(2):270-8
references: 11803143
references: N Engl J Med. 1999 Apr 15;340(15):1137-43
references: 10202164
references: Radiother Oncol. 2003 Sep;68(3):217-26
references: 13129628
references: Radiat Med. 2006 Feb;24(2):115-21
references: 16715672
references: J Clin Oncol. 2004 Mar 1;22(5):872-80
references: 14990643
references: J Clin Oncol. 1999 May;17(5):1339-48
references: 10334517
references: Int J Gynecol Cancer. 2008 Jan-Feb;18(1):80-4
references: 17466053
references: N Engl J Med. 1999 Apr 15;340(15):1144-53
references: 10202165
references: J Gynecol Oncol. 2008 Jun;19(2):129-34
references: 19471554
references: Gynecol Oncol. 2005 Jan;96(1):194-7
references: 15589600
references: J Clin Oncol. 2011 May 1;29(13):1678-85
references: 21444871
references: J Clin Oncol. 2007 Jul 1;25(19):2804-10
references: 17502627
references: J Clin Oncol. 2000 Apr;18(8):1606-13
references: 10764420
references: N Engl J Med. 1999 Apr 15;340(15):1154-61
references: 10202166